Solutions for the Interaction of Tumor Cells and Fibroblasts
Relying on the technology platform of the tumor microenvironment center, Alfa Oncology provides comprehensive solutions the study of the interactions between tumor cells and cancer-associated fibroblasts (CAFs), helping researchers to successfully achieve their research goals.
Fibroblasts in normal tissues are derived from resting mesenchymal cells within the extracellular mesenchyme (ECM) of the tumor microenvironment (TME). They can be activated during wound healing, tissue inflammation and fibrosis to promote repair and regeneration. The most unique feature of CAFs is their strong pro-ECM synthetic function. CAFs also produce a variety of growth factors and pro-inflammatory cytokines, in particular transforming growth factor-β (TGF-β), vascular endothelial growth factor (VEGF), interleukin 6 and CXC chemokine 12 (C-X-). C motif chemokine ligand 12 (CXCL12), promote tumor angiogenesis and recruit immunosuppressive cells to the tumor microenvironment to induce tumor immune evasion.
Cancer-associated fibroblasts have been found to promote tumor growth. They do so through many different mechanisms, particularly angiogenesis, metastasis and immune escape, and alteration of the tumor microenvironment (TME). CAFs express various cytokines and factors that activate and contribute to pathways that promote tumorigenesis. They may disrupt normal cellular functions, such as cell cycle regulation and cell death, or signal to specific cell types to mobilize and activate their pro-tumorigenic effects. In addition, CAFs have been found to act on tumor cells in ways that are specific to tumor cell types.
Cancer-associated fibroblasts (CAFs) are a group of activated fibroblasts with significant heterogeneity and plasticity in the tumor microenvironment. They secrete a variety of active factors to regulate tumorigenesis, progression, metastasis, and therapeutic resistance. Although most studies have shown that CAFs have significant pro-tumorigenic functions, there is evidence that they may have some tumor suppressive functions in early tumor stages. There are still many challenges in the study of CAFs, and the heterogeneity of their origin, phenotype and function, and their interactions with tumor cells are a major difficulty and hot spot. Alfa Oncology has established an innovative tumor microenvironment center technology platform and is developing several technologies aimed at studying the interactions between fibroblasts and tumor cells and their mechanisms on tumor metastasis, providing a theoretical basis for targeted therapies based on the interactions between fibroblasts and tumor cells.
Interactions between individual cells and adjacent cells determine the realization of cellular functions and cellular morphology. Understanding the mechanism of intercellular interactions is important for cell biology, especially in the fields of cancer therapy and stem cell regenerative medicine. Microfluidic technology can achieve single-cell manipulation at the order of magnitude, and has become one of the most promising single-cell analysis techniques in recent years. The application of microfluidic technology in single-cell pairing, fusion, migration, and cell-to-cell immune response is discussed, and the application prospects of microfluidic microarrays are prospected with organ-on-a-chip as an example. Using this technology, it is possible to deeply study the molecular mechanism and signaling pathway of tumor cell - CAFs interaction, inhibit CAF activation or target CAF, and provide theoretical guidance and basis for the clinical treatment of tumors.
Tumor Animal models include spontaneous tumor animal models, induced tumor animal models, transplanted tumor animal models and human tumor xenograft tumor models. The establishment of tumor animal models can study the interaction between tumor cells and CAFs and its molecular mechanism of action, evaluate the efficacy of anti-tumor immunotherapy, and to provide theoretical guidance for the anti-cancer treatment strategy using CAF as the targeting substrate.
Alfa Oncology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.